中国科学院深海科学与工程研究所研究员杜梦然被《自然》称为"深潜者"，榜单强调她在海平 面9000米以下发现了地球上最深的动物生态系统，在海洋最底层"见证科学界前所未有的景 象"。 入选榜单的还有"开拓者宝宝"——美国超罕见病患儿KJ·马尔敦，他在六个月大时接受了首例个 性化CRISPR基因编辑技术疗法后，向世界展露出可爱笑容。这项新技术为罕见疾病治疗带来了 希望。 此外，美国疾病控制和预防中心前主任、微生物学家和免疫学家苏珊·莫纳雷兹，印度数据科学 家阿查尔·阿格拉瓦尔，美国加利福尼亚大学戴维斯分校物理学家托尼·泰森、南非公共卫生官员 普雷舍丝·马佐索，英国伦敦大学学院神经科学家萨拉·大不里士，巴西农业研究员卢西亚诺·莫 雷拉以及以色列系统生物学家伊法特·梅尔博也入选榜单。 ■ 资料图。本文来源 ：新华社 《自然》评出年度十大科学人物 梁文锋和杜梦然入 选 英国《自然》杂志网站8日发布2025年度十大科学人物榜单，中国人工智能企业深度求索创始人 梁文锋和中国科学院深海科学家杜梦然入选。 在这份榜单中，梁文锋被誉为"科技颠覆者"。《自然》称他创立的中国人工智能企业开发出 DeepSeek大语言模型"震惊了世界" ...

股票简称：百奥赛图 股票代码：688796 百奥赛图（北京）医药科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. （北京市大兴区中关村科技园区大兴生物医药产业基地宝参南街12号院） 首次公开发行股票科创板上市公告书 保荐机构（主承销商） 北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层 二〇二五年十二月九日 特别提示 百奥赛图（北京）医药科技股份有限公司（以下简称"百奥赛图"、"本公司"、 "发行人"或"公司"）股票将于 2025 年 12 月 10 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上市 初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 2 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、准确、 完整，承诺上市公告书不存在虚假记载、误导性陈述或者重大遗漏，并依法承担法律责 任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均不表明对 本公司的任何保证。 本 公 司 提 醒 广 大 投 ...

研究野猪迁徙示意图。 结果显示，亚洲野猪约在360万年前与东南亚近亲物种分家。随后，部分种群向北迁徙进入中国南部。 180万年前，另一支野猪继续向西北迁徙，跨越荒漠与山地，抵达中亚。到90万年前，中亚的野猪又分 化出新的分支，向更远的西方扩散，约62万年前，它们兵分两路，一支进入近东，另一支最终到达欧 洲，成为今日欧洲野猪的祖先。 这是一场跨越百万年的壮阔远征，而在这场漫长的迁徙中，野猪的基因也在悄然重塑自己。 在人类文明尚未诞生的远古时代，东南亚的热带雨林中生活着早期野猪。它们在茂密的林木间觅食、繁 衍，却不知自己即将成为跨越欧亚大陆、历经百万年演化的迁徙者。 "我们希望把野猪这段迁徙旅程的'拼图'补全。"中国农业科学院深圳农业基因组研究所副研究员王子帅 介绍，早期关于野猪起源与演化的研究，主要集中在东南亚与欧洲两端。科学家已确认家猪的祖先来自 东南亚，但从那里出发的野猪如何一路向北、向西，穿越中亚高原、再到达欧洲，却长期是演化研究中 的空白地带。 中亚地区地处欧亚大陆腹地，是生物地理学上东西方物种交流的重要通道。但在以往的遗传学研究中， 这里却像一块被忽略的拼图，使得科学界难以准确推断野猪迁徙的真实路径和 ...

Core Points - The EU has reached an agreement on new regulations that pave the way for the use of gene editing technology in agriculture, aimed at helping farmers cultivate healthier plant and animal varieties to address climate change challenges [1][3] - The new regulations exempt gene-edited organisms from the EU's GMO regulatory framework, distinguishing gene editing from traditional genetic modification by simulating natural breeding processes without introducing cross-species DNA [1][3] Industry Impact - The agricultural protection industry views this technology as essential for enhancing crop and livestock resilience against extreme weather, pests, and diseases, providing EU farmers a competitive edge against countries like the US that already permit gene editing [3][4] - The EU Council stated that the new regulations will make the EU food system safer and more sustainable, enabling the cultivation of crops that are more resilient to climate change and pests, with higher yields and reduced reliance on fertilizers and pesticides [3][4] Regulatory Changes - The new measures are expected to reduce administrative burdens while enhancing the competitiveness of breeding companies and farmers [4] - The regulations still require formal approval from the European Parliament and the EU Council before coming into effect [3] Stakeholder Reactions - The EU agricultural association Copa-Cogeca welcomed the agreement as a historic advancement and the only practical solution for farmers under the EU's Green Deal framework [5] - Environmental organization "Friends of the Earth" criticized the regulatory relaxation, labeling it as a deregulation of new genetically modified organisms and a "pass" for the biotechnology industry [6]

Core Viewpoint - Nanmo Biology focuses on the research, production, sales, and related technical services of genetically modified animal models, primarily using mice, rats, and nematodes as model organisms [1] Company Overview - The company utilizes gene editing technology to insert, delete, or modify endogenous genes, creating biological models that simulate specific physiological, pathological, and cellular characteristics of humans [1] - The genetically modified animal models produced by the company mainly refer to genetically modified mouse models [1] Strategic Positioning - The company does not engage in any technical collaboration or strategic partnership with Yizhiming [1]

11月24日-11月28日新股申购一览 | 公司发行市盈率 | 行业平均市盈率 39.7 | | --- | --- | | 同业可比公司 | 药康生物、南模生物、昭衍新药 | | 一句话亮点 | 公司是一家临床前CRO以及生物技术企业。公司 自主开发的基因编辑技术提供各类创新模式动物 | | | 临床前阶段的医药研发服务。 | *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 未来一周有2只新股分别干周一、周五申购,重点公司方面,摩尔 是公司是国内极少数具备全功能GPU研发能力的企业 | 摩尔线程 (科创板，688795) | | | | | --- | --- | --- | --- | | 申购日期 11月24日 周一 | | 申购代码 | 7877 | | 计算机、通信和其 所属行业 他电子设备制造业 | | 总市值 | 457.2 | | 公司发行市盈率 27.06 | | 行业平均市盈率 | 60.1 | | 同业可比公司 | 海光信息、寒武纪、风神股份 | | | | 句话亮点 | 公司是国内极少数具备全功能GPU研发能力的企 公司MTT S80显卡的单精度浮点算 ...

Core Insights - The article highlights the growing importance of biomanufacturing in China's economic strategy, positioning it alongside quantum technology and embodied intelligence as a key future industry [1] - The shift from a generics-based pharmaceutical industry to one focused on innovative drug development has garnered significant global attention [1] Industry Overview - Biomanufacturing is recognized for its potential to revolutionize various sectors, including healthcare and agriculture, with examples such as rice-derived human serum albumin and gene editing technologies [2] - The application of biomanufacturing extends to environmental solutions, such as biodegradable plastics and the production of hyaluronic acid using microorganisms [2] Health and Longevity - China's average life expectancy is projected to reach 79 years by 2024, reflecting advancements in healthcare, though challenges remain in managing diseases like Alzheimer's [3] - A shift in medical focus from treatment to prevention and health maintenance is emphasized, with early disease detection being crucial for improving life quality and reducing healthcare costs [4][5] Global Positioning - China is recognized as a leading player in the biotechnological field, competing closely with the US, and is noted for its cost-effective innovations in drug development [6][7] - The disparity in drug pricing between China and the US is highlighted, with Chinese drugs being significantly more affordable, enhancing accessibility [6] Future Prospects - The article discusses the potential for China's biomanufacturing sector to expand internationally, emphasizing the importance of addressing global health needs rather than solely focusing on high-profit markets [8] - The upcoming implementation of new regulations is expected to bolster the biopharmaceutical industry, positioning China as a global center for biotherapy [10] Areas of Growth - Four key areas for significant advancements in biomanufacturing are identified: biomedicine and high-end medical devices, agricultural biotechnology, bioplastics, and marine biomanufacturing [11][12]

Core Insights - The prevalence of thalassemia carriers in China exceeds 30 million, with an estimated number of severe patients in the tens of thousands [1][3][6] - Thalassemia is a hereditary hemolytic anemia caused by defects in globin genes, leading to ineffective erythropoiesis and varying degrees of chronic anemia [2][3] - The disease is primarily divided into α-thalassemia and β-thalassemia, with severe cases requiring lifelong blood transfusions and iron chelation therapy [2][3] Disease Characteristics - Thalassemia is often confused with iron deficiency anemia, but they have fundamentally different causes; thalassemia is genetic while iron deficiency anemia is acquired [2][3] - Severe thalassemia can lead to life-threatening complications, including organ damage and severe deformities in fetuses [3][4] Treatment Developments - Current treatment for severe thalassemia mainly relies on allogeneic hematopoietic stem cell transplantation, which faces challenges such as donor matching and high costs [4][5] - Emerging gene editing technologies, particularly base editing, show promise for potentially curing β-thalassemia in a single treatment [5][6] - Clinical trials have demonstrated that patients treated with gene editing have stable hemoglobin levels and no longer require regular blood transfusions [6][7] Future Directions - The research team plans to conduct long-term follow-up studies on treated patients to monitor the safety and efficacy of gene editing [7] - There are intentions to expand the application of gene editing technology to other rare blood disorders, such as sickle cell anemia [7] - The cost of gene editing treatments is expected to decrease with technological advancements and policy support, making it accessible to more patients [7][8] Public Awareness and Prevention - There is a significant need for increased public awareness regarding thalassemia, as many individuals lack basic knowledge about the disease and its screening [8] - Efforts are being made by health authorities to promote pre-pregnancy and prenatal screening for thalassemia, but misconceptions hinder effective prevention [8]

Group 1: Beidou Navigation Industry - The Beijing-Tianjin-Hebei region aims to promote the application of over 800,000 new Beidou independent positioning terminal products by 2027, with a total application scale reaching 5 million units [1] - The action plan targets the cultivation of 10 leading enterprises and 50 "specialized, refined, distinctive, and innovative" companies, aiming to create an industry cluster worth over 200 billion yuan [1] - Huatai Securities believes that the Beidou navigation application industry has broad prospects, driven by demand from smartphones, consumer electronics, and specialized industries [1] Group 2: Robotaxi Development - Alibaba's Gaode announced a partnership with XPeng to integrate Robotaxi services into its platform, marking a significant step in the autonomous driving sector [2] - Morgan Stanley predicts that the global Robotaxi and fully autonomous driving market could reach approximately $300 billion by 2035 [2] - CITIC Securities highlights that the smart vehicle sector is a key growth area, with expectations for a critical transition in smart driving chips by 2025 [2] Group 3: Robotics Industry - XPeng aims to achieve mass production of advanced humanoid robots by the end of 2026 and plans to open its robot SDK to global developers [3] - The humanoid robot industry is entering a phase of rapid development, with significant applications expected in industrial settings [3][5] - ByteDance's recruitment for a senior algorithm expert in humanoid robotics indicates a strong commitment to advancing in this cutting-edge field [5] Group 4: Energy Storage Market - As of September 2023, China's new energy storage installed capacity has surpassed 100 million kilowatts, growing over 30 times since the end of the 13th Five-Year Plan [4] - The global energy storage market is expanding rapidly, with domestic bidding for storage projects increasing by 30% year-on-year [4] - The transition of energy storage from a policy-driven option to a market-driven necessity is expected to drive significant growth in the sector [4] Group 5: Gene Editing and Biotechnology - United Therapeutics has initiated the first clinical trial for gene-edited pig kidney transplants in humans, marking a significant advancement in this field [6] - The FDA's approval for this trial indicates a shift from individual cases to larger-scale clinical studies, reflecting technological maturity [6] Group 6: Macro and Industry News - Beijing's municipal government is supporting the development of the brain-computer interface industry with a dedicated incubation fund [6] - Shanghai's action plan aims to enhance efficiency in logistics through the application of drones in commercial settings [6] - The eighth Hongqiao International Economic Forum highlighted the importance of collaboration in humanoid robot technology development [6]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [6]. Core Insights - The company leverages gene editing technology to create a comprehensive antibody drug development platform, focusing on innovative solutions [2][16]. - The company has shown significant revenue growth, with a projected revenue CAGR of over 40% from 2021 to 2024, and is expected to turn profitable in 2024 [28][30]. - The antibody development business is a key driver of growth, with a revenue CAGR of 53% from 2021 to 2024 [5][34]. Summary by Sections Company Overview - Established in 2009, the company has developed a full human antibody library using its proprietary RenMice® platform, launching the "Thousand Mice, Ten Thousand Antibodies" initiative in 2020 [3][17]. - The company has created over 1 million full human antibody sequences targeting more than 1,000 potential drug targets [3][17]. Financial Performance - In the first half of 2025, the company achieved revenue of 621 million yuan, a year-on-year increase of 51.3%, with a gross margin of 74.4% [3][30]. - The company is expected to achieve revenues of 14.2 billion yuan, 19.3 billion yuan, and 26.1 billion yuan from 2025 to 2027, with net profit growth rates of 323%, 103%, and 75% respectively [6][8]. Business Segments - The preclinical animal products and pharmacological services provide a stable foundation, with model animal sales reaching 274 million yuan in the first half of 2025, a 56% increase year-on-year [4][34]. - The antibody development business has become the core driver of performance, with 163 million yuan in revenue in the first half of 2025, a 38% increase year-on-year [5][34]. Market Position - The company has established partnerships with the top ten global pharmaceutical companies, leveraging its expertise in gene editing and model animals [4][21]. - The antibody drug market is experiencing rapid growth, with the global antibody drug market projected to reach 2.704 trillion USD in 2024, growing to 4.634 trillion USD by 2031 [47][49].